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BACKGROUND: There is accumulating evidence that galanin receptors (GALRs) may be tumor suppressors in head and neck squa-
mous cell carcinoma (HNSCC). Promoter methylation status and gene expression were assessed in a large panel of head and neck
primary tumors, based on the hypothesis that cytosine-guanine dinucleotide (CpG) hypermethylation might silence the galanin recep-
tor 2 (GALR2) gene. METHODS: GALR2 expression was examined in a panel of cell lines by using quantitative reverse transcription
polymerase chain reaction (RT-PCR). The methylation status of the GALR2 promoter was studied using quantitative methylation-
specific PCR (Q-MSP). UM-SCC-1 was stably transfected to express GALR2. RESULTS: GALR2 expression was suppressed in UM-SCC
cell lines, whereas nonmalignant cell lines exhibited stable expression. GALR2 methylation found in 31 of 100 (31.0%) tumor specimens
was significantly correlated with the methylation status of both GALR1 and Galanin. The observed GALR2 promoter hypermethylation
was statistically correlated with a decrease in disease-free survival (log-rank test, P5.045). A multivariate logistic-regression analysis
revealed a high odds ratio for recurring methylation of GALR2 and the gene pair GALR2 and Galanin, 8.95 (95% confidence interval,
2.29-35.03; P5.024) and 9.05 (95% confidence interval, 1.76-46.50; P5.008), respectively. In addition, exogenous expression of
GALR2 suppressed cell proliferation in UM-SCC-1 cells with hypermethylated Galanin and GALR2-proficient cell lines. CONCLUSIONS:
Frequent promoter hypermethylation in association with prognosis, and growth suppression after re-expression, supports the hypoth-
esis that GALR2 may act to suppress tumor activity. GALR2 is a potentially significant therapeutic target and prognostic factor for
this cancer type. Cancer 2014;120:205–13. VC 2013 American Cancer Society.
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INTRODUCTION
Galanin receptors are members of the G protein–coupled receptor (GPCR) superfamily encoded byGALR1,GALR2, and
GALR3. Binding of the peptide galanin activates these receptors and stimulates numerous signal transduction and integra-
tion pathways.1 Recent findings support a growth regulatory function for GALR1 because antibody blocking of the recep-
tor enhances proliferation of head and neck squamous cell carcinoma (HNSCC) cells, and Galanin and GALR1 induce a
marked and prolonged ERK1/2 activation, up-regulation of p27Kip1 and p57Kip2, down-regulation of cyclin D1, and con-
sequent inhibition of cell proliferation.2 Furthermore, expression-negative squamous cell cancers and cell lines exhibit hy-
permethylation of cytosine-guanine dinucleotide (CpG) islands in the Galanin and GALR1 promoter region.3,4
Moreover, Galanin and GALR2 induce up-regulation of p27Kip1 and p57Kip2 and cyclin D1 down-regulation. These
effects are similar to GALR1 signaling, but GALR2 also induces caspase-3–dependent apoptosis, which is not observed
with GALR1.5 Furthermore, other recent studies have shown that reintroduction of GALR2 into solid tumor cells, includ-
ing neuroblastoma and pheochromocytoma cells, increases susceptibility to galanin-induced apoptosis and growth inhibi-
tion.6,7 Collectively, these studies on the functions of Galanin, GALR1, and GALR2 have led to improved understanding
of cancer.
Aberrant DNA methylation patterns can be useful to assess clinical outcomes. We recently defined the methylation
profiles of Galanin and GALR1 in HNSCC tumors, at the time of diagnosis and during subsequent follow-up, and
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evaluated the significance of methylation for prognosis
and as a biomarker for risk of recurrence.3,4 Hypermethyl-
ation of GALR2 has been described in several cancers,
including colorectal cancer, breast cancer,8 and hepatocel-
lular carcinoma.9 However, these studies did not include
a clinical association study. The purpose of this study was
to first define a GALR2, GALR1, and Galanin methyla-
tion profile in HNSCC tumors analyzed at the time of di-
agnosis and to evaluate its significance in prognosis as well
as its value as a biomarker for recurrence.
Results of this study indicate that loss of GALR2
expression is associated with hypermethylation of the pro-
moter region. Moreover, assessment of tumor specimens
confirmed that hypermethylation is common in patient
tumors and is associated with GALR2 methylation status
and disease-free survival (DFS). Finally, the restoration of
GALR2 expression in HNSCC cells resulted in the inhibi-
tion of colony formation in response to Galanin stimula-
tion, thereby supporting the hypothesis that this molecule
plays a tumor-suppressive role in HNSCC. Therefore,
GALR2 could be inactivated via promoter hypermethyl-
ation in human head and neck cancer cells and tumors,
and hypermethylation of GALR2 could be a critical event
in the genesis of HNSCC.
MATERIALS AND METHODS
Tumor Samples and Cell Lines
Tumor specimens were obtained during surgery from 100
primary HNSCC samples. All patients were treated at the
Department of Otolaryngology, Hamamatsu University
School of Medicine. Clinical information was obtained
from clinical records. The mean age was 63.9 years (range,
39-90 years), and the male:female ratio was 78:22.
Matched pairs of head and neck tumor and adjacent nor-
mal mucosal tissues were obtained from the surgical speci-
mens of 36 patients for initial methylation screening.
DNA and complementary DNA (cDNA) from 12 UM-
SCC cell lines were kindly provided by Dr. Thomas E.
Carey of the University of Michigan and were validated
by genotyping in his laboratory.
Bisulfite Modification, Quantitative Methylation-
Specific Polymerase Chain Reaction Analysis,
and Immunohistochemistry
Genomic DNA was extracted using the Wizard Genomic
DNA Purification Kit (Promega, Madison, Wis). Bisul-
fite modification of genomic DNA was carried out as
described.3 Promoter methylation levels of GALR2 were
determined using quantitative methylation-specific poly-
merase chain reaction (Q-MSP) with the TaKaRa
Thermal Cycler Dice Real Time System TP800 (TaKaRa,
Tokyo, Japan). The Q-MSP primers for methylated
DNA were Q-MSP-GALR2-F (50-CGATTGCGGGG
GTTGGAGTTCGGA-30) and Q-MSP-GALR2-R (50-
CCAACAACGACCGACGACGCTA-30), and Q-MSP-
ACTB-F (50-TGGTGATGGAGGAGGTTTAGAAGT-30)
and Q-MSP-ACTB-R (50-AACCAATAAAACCTACT
CCTCCCTTAA-30). A standard curve was generated
using serial dilutions of EpiScope Methylated HeLa
genomic DNA (TaKaRa). The normalized methylation
value (NMV) was defined as follows: NMV5 (GALR2-S/
GALR2-FM)/(ACTB-S/ACTB-FM), where GALR2-S and
GALR2-FM represent GALR2 methylation levels in the
sample and universal methylated DNAs, respectively,
whereas ACTB-S and ACTB-FM correspond to b-actin in
the sample and universal methylated DNAs, respectively.
To analyze the methylation status of GALR1,3 Galanin,4
p16,10 RASSF1A,11 MGMT,12 DAPK,12 and DCC13 pri-
mers, conditions as described previously were used. In
addition, vascular endothelial growth factor (VEGF) and
cyclin D1 immunohistochemistry analysis was carried out
as described.3,14,15
Direct Bisulfite Sequencing Analysis for GALR2
Bisulfite-treated DNA was amplified by bisulfite sequenc-
ing PCR (BSP) with a pair of primers that were specific
for modified upper-strand DNAs but did not contain any
CpG sites in their primers. The primer set was
50-GTTTGGTTAGTTTAGAATTT-30 (forward) and
50-AACCTTACCTCATCTAA AC-30 (reverse). The
PCR products were 217 base pairs (bp) in length. Direct
bisulfite sequencing analysis was carried out as described.3
RNA Extraction and Quantitative-RT-PCR
Total RNA was isolated using the RNeasy Mini Kit (Qia-
gen) and treated with Ribonuclease-Free deoxyribonucle-
ase (DNase; Qiagen). The cDNA was generated from
DNase-treated total RNA using Random primers (Invi-
trogen) with Superscript II reverse transcriptase (Invitro-
gen). Primers were designed as follows: GALR2 forward,
50-CGACCTGTGTTTCATCCTGTG-30 and GALR2
reverse, 50-GGTAGCGGATGGCCAGATA-30; GAPDH
forward, 50-GCACCGTCAAGGCTGAGAAC-30 and
GAPDH reverse, 50-TGGTGAAGACGCCAGTGGA-30.
For comparisons between samples, the messenger RNA
(mRNA) expression of the target genes was normalized to
GAPDHmRNA expression.
Reactivation of GALR2 Expression
At 1 hour after plating, cultures were incubated for 48
hours with 5-azacytidine (15 lg/mL, 30 lg/mL; Sigma)
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followed by 24 hours with 300 nM Tricostatin A (TSA;
Sigma).3
Plasmid Constructs and Growth Suppression
Analysis
UM-SCC-1 was cultured in Dulbecco’s modified Eagle
medium (Life Technologies) supplemented with 10%
heat-inactivated fetal bovine serum at 37C in 5% CO2.
The GALR2 sequence was obtained from a human cDNA
library (Invitrogen), hemagglutinin-tagged on the
COOH terminal end, and subcloned into the pcDNA3
vector (Invitrogen) containing an internal ribosomal entry
site (Ires) and green fluorescent protein (GFP) sequence.
The pCMVIresGFP vector was used as a transfection con-
trol. The UM-SCC-1-GALR2 and UM-SCC-1-mock
cells were established by transfecting with pCMVGALR2-
HAIresGFP or pCMVIresGFP, respectively, using Lipo-
fectAMINE (Invitrogen), followed by selection for GFP-
positive cells. At 24 hours after plating, stably transfected
cells were fed with serum-free medium containing 0.1%
bovine serum albumin for 24 hours to induce quiescence,
and then 1 lmol/L galanin (Anaspec) was added. Cell
proliferation was measured by counting cells with a
Coulter counter model Z1 (Beckman Coulter). Immuno-
blotting and immunocytochemistry analyses were carried
out as described.5
Data Analysis and Statistics
Receiver operating characteristic (ROC) curve analysis
was performed using the NMV for the 36 HNSCC and
Figure 1. Diagrammatic representation of the GALR2 gene methylation analysis using the quantitative methylation-specific PCR
(Q-MSP) assay, expression by quantitative reverse transcription polymerase chain reaction (Q-RT-PCR), and bisulfite sequencing
analysis in UM-SCC cell lines. (A) GALR2 CpG sites within expanded views of the promoter region relative to the transcription
start site (TSS). (B) Representative examples of Q-MSP of GALR2 in UM-SCC, indicating normal cell lines that are highly methyl-
ated (normalized methylation value [NMV]>0.038) (UM-SCC) or unmethylated (NMV<0.038). **P<.01. (C) Summary of direct
bisulfite sequencing analysis of GALR2 in UM-SCC cell lines. The numbers on the top row indicate the CpG dinucleotide (labeled
1-18 in panel A) in the amplicon. (D) Relative messenger RNA (mRNA) expressions as assessed by Q-RT-PCR of GALR2 in 12 UM-
SCC cell lines and normal cell lines. *P<.05. (E) The effect of treatment with 5-azacytidine (5-AZA) and TSA on GALR2
expression.
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36 adjacent normal mucosal tissues by StatMate IV (ATMS
Co, Ltd, Tokyo, Japan). By using this approach, the area
under the ROC curve identified optimal sensitivity and
specificity levels at which the normal tissues could be distin-
guished from HNSCC tissues, and corresponding NMV
thresholds were calculated for GALR2. The cutoff value
determined from this ROC curve was applied to determine
the frequency ofGALR2methylation in this study.
For frequency analysis in contingency tables, statisti-
cal analyses of associations between variables were per-
formed by Fisher’s exact test. In the colony-formation
assay, comparisons and tests for statistical significance
were made by the student t test. The disease-free interval
was measured from the date of the treatment to the date
when locoregional recurrence or distant metastasis was
diagnosed. DFS probabilities were estimated by the
Kaplan-Meier method, and the log-rank test was applied
to assess the significance of differences among actuarial
survival curves. Multivariate logistic-regression analysis
was used to determine the predictive value of the prognos-
tic factors.16,17 Global methylation value is defined as the
ratio between the number of methylated genes to the total
number of examined genes in each sample. A significant
difference was identified when the probability was less
than 0.05. Statistical analysis was performed using Stat-
Mate IV (ATMSCo, Ltd).
RESULTS
UM-SCC Cell Lines
Forward primers for Q-MSP contained 1 to 3 CpG dinu-
cleotides. Reverse primers for Q-MSP included 12 to 15
CpG dinucleotides (Fig. 1A). In all cancer cell lines with
reduced expression, the NMV of GALR2 was significantly
higher than in normal cell lines (Fig. 1B). Direct bisulfate
DNA sequencing was carried out to assess the percentage
of CpG alleles methylated in the GALR2 50 region. The
percentage of methylated alleles for each of the 18 differ-
ent CpG sites is summarized in Figure 1C for 12 UM-
SCC cell lines. The concordance between mRNA expres-
sion levels and aberrant methylation of GALR2 was nearly
identical (Fig. 1C). We analyzed 12 UM-SCC cell lines
for mRNA expression of GALR2 by using quantitative
RT-PCR and found lower expression in cancer cell lines
than in normal cell lines (Fig. 1D).
To establish that methylation was responsible for
silencing of the GALR2 gene expression, we evaluated 3
cell lines (UM-SCC-1, UM-SCC-23, and UM-SCC-54).
These cell lines, that exhibited absence of GALR2
expression and hypermethylation, were cultured with
5-azacytidine plus TSA. The results show that GALR2
expression was up-regulated after treatment (Fig. 1E).
Initial Screening: Matched Pairs of Head
and Neck Tumors and Adjacent Normal
Mucosal Tissues
Initially, GALR2 promoter methylation status was ana-
lyzed in 36 cancerous and paired noncancerous mucosae
Figure 2. GALR2 methylation analysis using the quantitative
methylation-specific PCR (Q-MSP) assay in head and neck
squamous cell carcinoma (HNSCC) tumor samples. (A) Pat-
tern of hypermethylation observed in matched pairs of head
and neck tumors and adjacent normal mucosal tissues. (B) Re-
ceiver operator characteristic (ROC) curve analysis of normal-
ized methylation value (NMV). AUROC indicates area under
the ROC curve. (C) DNA samples from 100 untreated primary
tumors tested with the same primers. The location of the NMV
cutoff for GALR2 (0.038) used for the data is indicated by a
straight arrow. (D) Relative GALR2 messenger RNA (mRNA)
expression as assessed by Q-RT-PCR in 10 tumor specimens
that were also evaluated for GALR2 promoter methylation.
Specimens H-2, H-5, H-23, H-33, H-40, and H-88 exhibited
promoter methylation (M), but H-13, H-34, H-57, and H-110 did
not (U). (E) Percentage of 100 HNSCC patients with epige-
netic alteration in GALR2, GALR1, and Galanin genes, and rela-
tive frequency of gene hypermethylation events.
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by using Q-MSP. Promoter methylation levels were rep-
resented by NMVs, which is the ratio of methylated DNA
at the target sequence in each specimen to a fully methyl-
ated control DNA. The GALR2methylation level was sig-
nificantly higher in primary HNSCCs than in
noncancerous mucosal tissues (median NMV5 0.154
versus 0.08, P< .001; Wilcoxon matched pairs test and
paired student t test; Fig. 2A).
GALR2 promoter hypermethylation exhibited
highly discriminative ROC curve profiles, which clearly
distinguished HNSCC from normal mucosal tissues
(AUROC5 0.8495). The ROC curve with correspond-
ing areas under the curve for GALR2 of HNSCC versus
normal mucosal tissues is presented in Figure 2B. The cut-
off NMV for GALR2 (0.038) was chosen from the ROC
curve to maximize sensitivity (61.1%) and specificity
(100%) (Fig. 2B).
Clinicopathological Characteristics of 100
Primary HNSCC Samples
Among 100 DNA samples from previously untreated pri-
mary tumors tested with the same primers, a specimen
was classified as methylated when its NMV exceeded
0.038. The GALR2 promoter was methylated in 31 of
100 (31.0%) cases and unmethylated in 69 (69.0%) (Fig.
2C). GALR2 expression analyzed by Q-RT-PCR identi-
fied 6 tumors, namely, H-2, H-5, H-23, H-33, H-40,
and H-88 with strong methylation signals, which exhib-
ited little mRNA expression. In contrast, 4 tumors (H-13,
H-34, H-57, and H-110) without GALR2 promoter
methylation exhibited relatively robust mRNA expression
(Fig. 2D). Methylation of GALR2 significantly correlated
with DAPK (P5 .004), H-cadherin (P5 .0003),
COL1A2 (P5 .017), GALR1 (P5 .027), and Galanin
methylation status (P5 6.43325) ; Table 1). Specifi-
cally, GALR1 exhibited promoter hypermethylation in
38% (38 of 100) and Galanin in 24% (24 of 100) of the
tumors.3,4 A representative methylation analysis for
GALR2, GALR1, and Galanin in tumors is shown in Fig-
ure 2E. Eleven percent (11 of 100) of the tumors included
all 3 hypermethylated genes: 19% had 2 hypermethylated
genes, 22% had only a single hypermethylated gene, and
48% had no methylated gene (Fig. 2E).
Prognostic Value of the GALR2 and Promoter
Methylation of Other Genes
We found that the presence ofGALR2 promoter methyla-
tion was associated with a statistically significant decrease
in DFS (log-rank test, P5 .0445) (Fig. 3A). Methylation
of both Galanin and GALR2 was associated with a DFS
TABLE 1. GALR2 Gene Methylation Status in
HNSCC Primary Samples
Patient and Tumor
Characteristics
(n 5 100)
Methylation
P Valuea
Present
(n 5 31)
Absent
(n 5 69)
Age, y
70 and older (29) 8 21
Under 70 (71) 23 48 .812
Sex
Male (78) 20 58
Female (22) 11 11 1
Smoking status
Smoker (69) 19 50
Nonsmoker (31) 12 19 1
Alcohol exposure
Ever (58) 17 43
Never (42) 14 26 1
Tumor size
T1-2 (49) 12 37
T3-4 (51) 19 32 .198
Lymph node status
N0 (44) 13 31
N1 (56) 18 38 .830
Stage
I, II, III (45) 13 32
IV (55) 18 37 .828
VEGF expression
High expression (52) 16 36
Low expression (48) 15 33 1
Cyclin D1 expression
High expression (33) 12 21
Low expression (67) 19 48 1
p16 methylation
Yes (54) 20 34
No (46) 11 35 .195
RASSF1A methylation
Yes (22) 5 17
No (78) 26 52 .438
MGMT methylation
Yes (34) 12 22
No (66) 19 47 1
DAPK methylation
Yes (39) 19 20
No (61) 12 49 .004b
E-cadherin methylation
Yes (40) 15 25
No (60) 16 44 1
H-cadherin methylation
Yes (37) 20 17
No (63) 11 52 .0003b
DCC methylation
Yes (58) 22 36
No (42) 9 33 .085
COL1A2 methylation
Yes (52) 22 30
No (48) 9 39 .017b
GALR1 methylation
Yes (38) 17 21
No (62) 14 48 .027b
Galanin methylation
Yes (24) 16 8
No (76) 15 61 6.43 3 1025b
a Fisher’s exact probability test.
bP < .05.
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rate of 12.5%, as compared with 61.6% in the absence of
methylation of these genes (log-rank test, P5 .0008)
(Fig. 3B). Methylation of any 3 genes was associated with
a DFS rate of 28.3%, as compared with 61.6% in the ab-
sence of methylation of these genes (log-rank test,
P5 .0022) (Fig. 3C). In GALR2, GALR1, and Galanin,
the DFS rates for zero methylated genes, 1 to 2 methyl-
ated genes, and all 3 methylated genes, were 61.6%,
41.7%, and 0%, respectively (log-rank test, P5 .0016;
Fig. 3D). Multivariate logistic-regression analysis, which
involved age, sex, smoking status, alcohol intake, stage
grouping and methylated genes, indicated the estimated
odds of recurrence associated with methylation of GALR2
and the other 8 genes. When GALR2 was methylated in
the primary tumor, the adjusted odds ratio for recurrence
was 3.12 (95% confidence interval [CI] 5 1.16-8.43;
Figure 3. Kaplan-Meier survival curves for patients with head and neck squamous cell carcinoma (HNSCC). Survival time by (A)
GALR2 methylation status; (B) GALR2 and Galanin methylation status; (C) GALR2, GALR1, and Galanin methylation status; (D)
number of unfavorable events. Joint analyses of 3 genes showed a significant trend for poorer DFS as the number of unfavorable
events increased (P5.0016); (E) GALR2 methylation status and VEGF expression status.
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P5 .024). Patients with methylation of both Galanin and
GALR2 had a significantly higher odds ratio for recurrence of
9.05 (95% CI5 1.76-46.5; P5 .008), compared with those
not exhibiting methylation for this pair of genes (Fig. 4A).
Multivariate logistic-regression analysis, which involved age,
sex, smoking status, alcohol intake, global methylation value,
and methylated genes, indicated the estimated odds of recur-
rence associated with methylation of GALR2, GALR1, and
Galanin. GALR2 methylation is an independent biomarker
on its own, and patients with methylation of GALR2 exhib-
ited a high odds ratio for recurrence of 2.71 (95% CI5 1.01-
7.31; P5 .0489) (Fig. 4B).
Suppression of Cell Growth After Restoration of
GALR2 Expression
The UM-SCC-1 cell line, which exhibits extensive hyper-
methylation and expresses no GALR1 and GALR2 mes-
sage, was used for assessment of exogenous GALR2 re-
expression and effects on cell proliferation in response to
galanin stimulation. UMSCC-1 cells transfected with
wild-type GALR2 in the pCMVIresGFP or pCMV
GALR2HAIresGFP constructs were assessed for GALR2
expression by immunoblotting (Fig. 5A) and immunocy-
tochemistry (Fig. 5B) with HA-tag–specific antibody
(Fig. 5A). GALR2-HA expression was clearly detected,
and GALR2-HA localized to the cytoplasmic membrane
as expected for a GPCR (Fig. 5B). Treatment with 0.5
lM Galanin suppressed cell proliferation in UM-SCC-1
GALR2HA cells by 33% (P< .01) relative to the vector
alone in transfected cells (Fig. 5C). Thus, GALR2 inhibits
tumor cell proliferation in response to Galanin
stimulation.
DISCUSSION
Our preliminary analysis showed that silencing of the
GALR1 gene by methylation may be a critical event in
tumor progression of HNSCC, because 18q loss of heter-
ozygosity is associated with tumor progression,18 and
GALR1 promoter methylation was associated with
reduced overall survival rates.3 Furthermore, the methyla-
tion of Galanin significantly correlated with GALR1
methylation and reduced DFS. The methylation of the
gene pair Galanin and GALR1 in the primary tumor was
associated with the most significant odds ratio of recur-
rence,4 whereas another study concluded that GALR1
induces cell cycle arrest, and GALR2 induces both cell
cycle arrest and apoptosis in HNSCC following Galanin
treatment.2,5 Results of this study indicated that aberrant
cycling D1 expression and DNA methylation of GALR2
is associated with prognosis.
In regard to GALRs, another study demonstrated
that induction of high levels of GALR2 expression medi-
ated apoptosis and inhibition of cell proliferation in neu-
roblastoma cells, but GALR1-expressing cells exhibited
reduced potency to decrease cell proliferation.6 Further-
more, the mitogenic effects of Galanin on small cell lung
carcinoma cells are mediated by a single galanin receptor
subtype, GALR2.19 Although GalR2 knockout mice are
known to exhibit anxiety- and depression-related behav-
iors, no data are available indicating that they are suscepti-
ble to spontaneous tumor development. Thus, the role of
GALR2 in inducing tumorigenesis and the mechanisms
involved are not well-established.
Recent advances in molecular biology have made it
possible to apply new strategies such as gene- and
molecular-targeted therapies as suitable cancer treatments.
Figure 4. Multivariate logistic-regression model. (A) Odds
ratios for recurrence are reported on the basis of the multi-
variate logistic regression model adjusted for age (70 and
older versus <70), sex, smoking status, alcohol intake, and
stage (I, II, III, versus IV). A multivariate logistic regression
analysis showed the estimated odds of recurrence to be
associated with the methylation of GALR2 and 8 other genes.
(B) Odds ratios for recurrence are reported on the basis of
the multivariate logistic regression model adjusted for age
(70 years and older versus <70 years), sex, smoking status,
alcohol exposure, and global methylation value (6 to 8 versus
<6). CI5 confidence interval.
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Despite these advances, applications for HNSCC have
trailed behind innovative treatments for breast, renal, and
colorectal carcinomas.2,5 GPCRs belong to a superfamily
of cell surface signaling proteins that play pivotal roles in
many physiological functions and in multiple diseases,
including the development of cancer and cancer metasta-
sis.20 In recent years, several studies have suggested that
these neuropeptides function as tumor suppressors and
possess potent antitumor properties for human cancers.
Hypermethylation of GALR2 has been described in sev-
eral cancers, including colorectal cancer, breast cancer,8
and hepatocellular carcinoma.9 Despite our understand-
ing of adenocarcinoma, hypermethylation of GALR2 in
squamous cell carcinoma (SCC) such as head and neck,
esophageal, lung, and cervical cancers, is an area that
remains to be investigated. In this regard, it is worth not-
ing that GALR2 promoter methylation and silencing may
occur frequently in HNSCC and this association with
GALR1methylation, Galaninmethylation, and decreased
survival, is statistically significant.
Recently, GALR2 was identified as a chemosensitive
methylation candidate for bevacizumab regimens used to
treat colorectal cancer cells.21 A previous study from our
laboratory showed that high VEGF expression was signifi-
cantly related to a decrease in survival, whereas loss of
VEGF results in a significantly improved prognosis.14
Furthermore, Yamatodani et al reported significant inhib-
itions of bevacizumab on angiogenesis and cancer cell sur-
vival in HNSCC.22 Our results indicate that
hypermethylation of GALR2 with a high expression of
VEGF is associated with a DFS rate of 10.5%, compared
with 52.2% for other conditions (log-rank test,
P5 .0096) (Fig. 3E). Because the exact mechanisms of
the functions ofGALR2 and VEGF genes in tumorigenesis
are still unknown, it will be interesting to elucidate the
relationships between the GALR2 and VEGF genes. At
present, only a limited number of efficient methylation
markers of chemosensitivity have been discovered. Good
response to chemotherapy has been described for other
DNA repair genes such as WRN methylation for irinote-
can in colorectal tumors23 and IGFBP-3 methylation for
cisplatin in lung tumors.24 Recently, methylation of
DAPK was reported to be associated with cetuximab and
erlotinib resistance in non–small cell lung cancer and
HNSCC cell lines.25 Because our study did not include a
patient receiving chemotherapy, both GALR2 methyla-
tion and VEGF expression should be investigated as
potential chemosensitive candidates for targeted therapy
in large clinical cohorts.
In this study, GALR2 expression was frequently
absent in HNSCC. The GALR2 expression-suppressive
UM-SCC cell lines were hypermethylated in the CpG
islands of the GALR2 promoter region. Furthermore, we
demonstrated that re-expression of GALR2 in transfected
cells results in galanin-induced inhibition of cell prolifera-
tion. In 100 primary tumor samples, hypermethylation of
the GALR2 promoter (31%) was also documented in a
similar proportion to the hypermethylation of promoters
of other genes (24%-58%). Importantly, there is a signifi-
cant correlation between GALR2 promoter methylation
and Galanin methylation status in primary samples. Our
preliminary studies have shown that GALR1 and Galanin
methylation were also found in 38% and 24% of primary
tumor specimens, respectively.3,4 Similarly, concurrent
Figure 5. Exogenous GALR2 expression in transfected UM-
SCC-1 cells. (A) Immunoblotting shows exogenous GALR2
expression in pCMVGALR2IresGFP-transfected cells detected
using antibody to hemagglutinin (HA)-tag. Lanes labeled
mock and GALR2HA contain protein lysates from mock-
transfected and GALR2HA-transfected UM-SCC-1 cells (UM-
SCC-1-GALR2), respectively. Lanes labeled mock1PNGase-F
and GALR2HA1PNGase-F contain protein from cell lysates
that were digested with N-glycosidase F. (B) Exogenous
GALR2 localizes to the cell membrane in UM-SCC-1-GALR2
cells. UM-SCC-1-GALR2 cells were stained with mouse mono-
clonal anti–HA-tag antibody and Hoechst 33342. Photo-
graphs show cells stained with Hoechst 33342 (upper left),
green fluorescent protein (GFP; upper right), HA-tag (lower
left), and the merged image (lower right); magnification
3400. (C) Relative colony-formation ability for UM-SCC-1.
The vector-transfected number of hygromycin B–resistant
colonies was set at 100%. Colonies larger than 1 mm were
counted, and the results are presented as the mean6 stan-
dard deviation (bars) of 3 separate experiments, each per-
formed in triplicate.
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analysis revealed that 11.0% of the tumors were com-
pletely methylated in all 3 genes; 41.0% exhibited methyl-
ation of either GALR2, GALR1, or Galanin; and 48.0%
exhibited no methylation in any of the 3 genes. A total of
52.0% of all cases exhibited identical promoter hyper-
methylation in at least 1 of the 3 genes investigated.
Patients who were identified with hypermethylation of
both GALR2 and Galanin genes experienced shorter DFS
than did patients exhibiting different genetic methylation
patterns. In multivariate logistic-regression analyses,
methylation of the GALR2 gene was associated with a sig-
nificant odds ratios of recurrence. The feasibility of clini-
cally useful epigenetic markers in HNSCC is becoming
clearer, not only through this study but also based on
results of a recently published study by Carvalho et al.26
Our findings support the translation of such methylation
markers into clinical practice, although additional pro-
spective studies will be required to validate these genes in
larger populations of patients with HNSCC.
Thus,GALR2 resembles other major tumor suppres-
sor genes in terms of frequency of aberrant promoter
methylation both in vitro and in vivo. In this study, we
showed for the first time, to our knowledge, that expres-
sion of GALR2 mRNA is lost in HNSCC as a conse-
quence of DNA methylation. Furthermore, silencing of
the GALR2 gene by methylation may be a critical event in
HNSCC. The current data suggest that GALR2, GALR1,
and Galanin are potentially significant therapeutic targets
and prognostic factors in HNSCC.
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